Introduction: The molecular pathogenesis of Alzheimer’s disease (AD) is still not clear, and the relationship between gene expression profile for different brain regions has not been studied. Objective: Bioinformatic analysis at the genetic level has become the best way for the pathogenesis research of AD, which can analyze the abovementioned relationship. Methods: In this study, the datasets of AD were obtained from the Gene Expression Omnibus (GEO), and Qlucore Omics Explorer (QOE) software was used to screen differentially expressed genes of GSE36980 and GSE9770 and verify gene expression of GSE63060. The Gene Ontology (GO) function enrichment analysis of these selected genes was conducted by Database for Annotation, Visualization, and Integrated Discovery (DAVID), and then the gene/protein interaction network was established by STRING to find the related proteins. R language was used for drafting maps and plots. Results: There were 20 differentially expressed genes related to AD selected from GSE36980 (p = 6.2e−6, q = 2.9422e−4) and GSE9770 (p = 3.3e−4, q = 0.016606). Their expression levels of the AD group were lower than those in the control group and varied among different brain regions. Cellular morphogenesis and establishment or maintenance of cell polarity were enriched, and LRRTM1 and RASAL1 were identified by the integration network. Moreover, the analysis of GSE63060 verified the expression level of LRRTM1 and RASAL1 in Alzheimer’s patients, which was much lower than that in normal people aged >65 years. Conclusions: The pathogenesis of AD at molecular levels may link to cell membrane structures and signal transduction; hence, a list of 20 genes, including LRRTM1 and RASAL1, potentially are important for the discovery of treatment target or molecular marker of AD.

1.
Joe
E
,
Ringman
JM
.
Cognitive symptoms of Alzheimer’s disease: clinical management and prevention
.
BMJ
.
2019
;
367
:
l6217
.
2.
Alzheimer’s Disease Facts and Figures. 2019
.
3.
Kasahara
M
,
Mizutani
T
.
[Neuropathological study on progression of the limbic degeneration in senile dementia of Alzheimer type]
.
No To Shinkei
.
1997
;
49
(
1
):
51
8
.
4.
Rinne
JO
,
Rinne
JK
,
Laakso
K
,
Paljärvi
L
,
Rinne
UK
.
Reduction in muscarinic receptor binding in limbic areas of Alzheimer brain
.
J Neurol Neurosurg Psychiatry
.
1984
;
47
(
6
):
651
2
.
5.
Price
JL
,
Ko
AI
,
Wade
MJ
,
Tsou
SK
,
McKeel
DW
,
Morris
JC
.
Neuron number in the entorhinal cortex and ca1 in preclinical Alzheimer disease
.
Arch Neurol
.
2001
;
58
(
9
):
1395
402
.
6.
Suva
D
,
Favre
I
,
Kraftsik
R
,
Esteban
M
,
Lobrinus
A
,
Miklossy
J
.
Primary motor cortex involvement in Alzheimer disease
.
J Neuropathol Exp Neurol
.
1999
;
58
:
1125
34
.
7.
Braak
H
,
Del Tredici
K
.
Alzheimer’s pathogenesis: is there neuron-to-neuron propagation?
Acta Neuropathol
.
2011
;
121
:
589
95
.
8.
Perl
DP
.
Neuropathology of Alzheimer’s disease
.
Mt Sinai J Med
.
2010
;
77
(
1
):
32
42
.
9.
Weller
RO
,
Nicoll
JA
.
Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain
.
Neurol Res
.
2003
;
25
(
6
):
611
6
.
10.
Ulamek-Koziol
M
,
Pluta
R
,
Bogucka-Kocka
A
,
Januszewski
S
,
Kocki
J
,
Czuczwar
SJ
.
Brain ischemia with Alzheimer phenotype dysregulates Alzheimer’s disease-related proteins
.
Pharmacol Rep
.
2016
;
68
:
582
91
.
11.
Hokama
M
,
Oka
S
,
Leon
J
,
Ninomiya
T
,
Honda
H
,
Sasaki
K
, et al
Altered expression of diabetes-related genes in Alzheimer’s disease brains: the hisayama study
.
Cereb Cortex
.
2014
;
24
:
2476
88
.
12.
Readhead
B
,
Haure-Mirande
JV
,
Funk
CC
,
Richards
MA
,
Shannon
P
,
Haroutunian
V
, et al
Multiscale analysis of independent Alzheimer’s cohorts finds disruption of molecular, genetic, and clinical networks by human herpesvirus
.
Neuron
.
2018
;
99
(
1
):
64
.
13.
Liang
WS
,
Dunckley
T
,
Beach
TG
,
Grover
A
,
Mastroeni
D
,
Ramsey
K
, et al
Neuronal gene expression in non-demented individuals with intermediate Alzheimer’s disease neuropathology
.
Neurobiol Aging
.
2010
;
31
(
4
):
549
66
.
14.
Sood
S
,
Gallagher
IJ
,
Lunnon
K
,
Rullman
E
,
Keohane
A
,
Crossland
H
, et al
A novel multi-tissue rna diagnostic of healthy ageing relates to cognitive health status
.
Genome Biol
.
2015
;
16
:
185
.
15.
Dekker
AD
,
Strydom
A
,
Coppus
AM
,
Nizetic
D
,
Vermeiren
Y
,
Naude
PJ
, et al
Behavioural and psychological symptoms of dementia in down syndrome: early indicators of clinical Alzheimer’s disease?
Cortex
.
2015
;
73
:
36
61
.
16.
Coleman
P
,
Federoff
H
,
Kurlan
R
.
A focus on the synapse for neuroprotection in Alzheimer’s disease and other dementias
.
Neurology
.
2004
;
63
(
7
):
1155
62
.
17.
Jack
CR
 Jr
,
Bennett
DA
,
Blennow
K
,
Carrillo
MC
,
Feldman
HH
,
Frisoni
GB
, et al
A/t/n: an unbiased descriptive classification scheme for Alzheimer’s disease biomarkers
.
Neurology
.
2016
;
87
(
5
):
539
47
.
18.
Supnet
C
,
Bezprozvanny
I
.
The dysregulation of intracellular calcium in Alzheimer disease
.
Cell Calcium
.
2010
;
47
(
2
):
183
9
.
19.
Joo
JY
,
Lee
SJ
,
Uemura
T
,
Yoshida
T
,
Yasumura
M
,
Watanabe
M
, et al
Differential interactions of cerebellin precursor protein (cbln) subtypes and neurexin variants for synapse formation of cortical neurons
.
Biochem Biophys Res Commun
.
2011
;
406
(
4
):
627
32
.
20.
Chen
H
,
Cheng
ZY
,
Pan
Y
,
Wang
Z
,
Liu
Y
,
Zhang
JQ
.
RASAL1 influences the proliferation and invasion of gastric cancer cells by regulating the RAS/ERK signaling pathway
.
Hum Cell
.
2014
;
27
(
3
):
103
10
.
21.
Chen
H
,
Zhao
JY
,
Qian
XC
,
Cheng
ZY
,
Liu
Y
,
Wang
Z
.
RASAL1 attenuates gastric carcinogenesis in nude mice by blocking RAS/ERK signaling
.
Asian Pac J Cancer Prev
.
2015
;
16
(
3
):
1077
82
.
22.
Chen
H
,
Yang
XW
,
Zhang
H
,
Yang
Q
,
Wang
Z
,
Liu
Y
, et al
In vivo and in vitro expression of the RASAL1 gene in human gastric adenocarcinoma and its clinicopathological significance
.
Oncol Lett
.
2012
;
3
(
3
):
535
40
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.